Clinicopathological and immunological characterization of RNA m⁶A methylation regulators in ovarian cancer

Abstract

Abstract Background N 6 ‐methyladenosine (m 6 A) modification is one of the critical gene regulatory mechanisms implicated in cancer biology. However, the roles of m 6 A regulators in ovarian cancer are still poorly understood. Methods We integrated multiple databases including Gene Expression Omnibus (GEO), ROC Plotter, Kaplan‐Meier Plotter, and Tumor Immune Estimation Resource (TIMER) to explore clinicopathological significance of m 6 A regulators in ovarian cancer. Results We showed that alterations in the expression of m 6 A regulators were related to the malignancy and poor prognosis of ovarian cancer. We found decreased YTHDC1 and increased RBM15 expressions were associated with ovarian cancer cell metastases and HNRNPC was a predictor of paclitaxel resistance. Moreover, dysregulated m 6 A regulators were enriched in the activation of cancer‐related pathways. Our results further demonstrated that the level of immune cell infiltration and the expression of various immune gene markers were closely associated with the expressions of specific m 6 A regulators (RBM15B, ZC3H13, YTHDF1, and IGF2BP1). Conclusions Our study establishes a new prognostic profile of ovarian cancer patients based on m 6 A regulators, and highlights the potential roles of m 6 A regulators in ovarian cancer development.